Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
National Institutes of Health · National Center for Advancing Translational Sciences · +1 more institution
Abstract
[Image: see text] The global pandemic of SARS-CoV-2, the causative viral pathogen of COVID-19, has driven the biomedical community to action—to uncover and develop antiviral interventions. One potential therapeutic approach currently being evaluated in numerous clinical trials is the agent remdesivir, which has endured a long and winding developmental path. Remdesivir is a nucleotide analogue prodrug that perturbs viral replication, originally evaluated in clinical trials to thwart the Ebola outbreak in 2014. Subsequent evaluation by numerous virology laboratories demonstrated the ability of remdesivir to inhibit coronavirus replication, including SARS-CoV-2. Here, we provide an overview of remdesivir’s…
Citation impact
- FWCI
- 19.85
- Percentile
- 100%
- References
- 94
Authors
7- RTRichard T. Eastman
National Institutes of Health, National Center for Advancing Translational Sciences
- JSJacob S. Roth
National Institutes of Health, Albert Einstein College of Medicine, National Center for Advancing Translational Sciences
- KRKyle R. Brimacombe
National Institutes of Health, National Center for Advancing Translational Sciences
- ASAnton Simeonov
National Institutes of Health, National Center for Advancing Translational Sciences
- MSMin Shen
National Institutes of Health, National Center for Advancing Translational Sciences
Topics & keywords
- Coronavirus disease 2019 (COVID-19)
- Pandemic
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Medicine
- Clinical trial
- Virology
- Viral replication
- Coronavirus
- Good health and well-being